|
Volumn 34, Issue 1, 2008, Pages 65-73
|
Analysis of Wegener's granulomatosis responses to rituximab: Current evidence and therapeutic prospects
a
Hôpital Cochin
*
(France)
|
Author keywords
ANCA associated vasculitis; Anti CD20 monoclonal antibody; Rituximab; Wegener's granulomatosis
|
Indexed keywords
AZATHIOPRINE;
CORTICOSTEROID;
COTRIMOXAZOLE;
CYCLOPHOSPHAMIDE;
EPRATUZUMAB;
HA20;
IMMUNOGLOBULIN;
INFLIXIMAB;
METHOTREXATE;
MONOCLONAL ANTIBODY;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
NEUTROPHIL CYTOPLASMIC ANTIBODY;
OCRELUZIMAB;
OFATUMUMAB;
RITUXIMAB;
TRU 015;
ANCA ASSOCIATED VASCULITIS;
B LYMPHOCYTE;
DRUG TOLERABILITY;
HISTOPATHOLOGY;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
PATHOPHYSIOLOGY;
PHARMACODYNAMICS;
REVIEW;
RHEUMATOID ARTHRITIS;
SYSTEMIC LUPUS ERYTHEMATOSUS;
TREATMENT RESPONSE;
UNSPECIFIED SIDE EFFECT;
VASCULITIS;
WEGENER GRANULOMATOSIS;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS AS TOPIC;
DRUG THERAPY, COMBINATION;
HUMANS;
IMMUNOLOGIC FACTORS;
IMMUNOSUPPRESSIVE AGENTS;
TREATMENT OUTCOME;
WEGENER GRANULOMATOSIS;
|
EID: 40749099315
PISSN: 10800549
EISSN: None
Source Type: Journal
DOI: 10.1007/s12016-007-8026-1 Document Type: Review |
Times cited : (23)
|
References (51)
|